Antipseudomonal agents exhibit differential pharmacodynamic interactions with human polymorphonuclear leukocytes against established biofilms of Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2198-2205

  Chatzimoschou, Athanasios ^a   Simitsopoulou, Maria ^a   Antachopoulos, Charalampos ^a   Walsh, Thomas J ^b   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CYSTIC FIBROSIS; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG FIBROSIS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; XTT ASSAY; CYTOLOGY; DRUG EFFECTS; IN VITRO STUDY; SPUTUM;

AMIKACIN; ANTI-BACTERIAL AGENTS; BIOFILMS; CEFTAZIDIME; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMANS; IN VITRO TECHNIQUES; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; SPUTUM;

EID: 84928901539     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04934-14     Document Type: Article

References (51)

1. Driscoll JA, Brody SL, Kollef MH. 2007. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67:351-368. http://dx.doi.org/10.2165/00003495-200767030-00003.
2. Gjodsbol K, Christensen JJ, Karlsmark T, Jorgensen B, Klein BM, Krogfelt KA. 2006. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 3:225-231. http://dx.doi.org/10.1111/j.1742-481X.2006.00159.x.
3. Lyczak JB, Cannon CL, Pier GB. 2002. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15:194-222. http://dx.doi.org/10.1128/CMR.15.2.194-222.2002.
4. Foweraker J. 2009. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 89:93-110. http://dx.doi.org/10.1093/bmb/ldn050.
5. Morita Y, Tomida J, Kawamura Y. 2014. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol 4:422. http://dx.doi.org/10.3389/fmicb.2013.00422.
6. Jensen PO, Givskov M, Bjarnsholt T, Moser C. 2010. The immune system vs. Pseudomonas aeruginosa biofilms. FEMS Immunol Med Microbiol 59:292-305. http://dx.doi.org/10.1111/j.1574-695X.2010.00706.x.
7. Williams BJ, Dehnbostel J, Blackwell TS. 2010. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15:1037-1056. http://dx.doi.org/10.1111/j.1440-1843.2010.01819.x.
8. Jesaitis AJ, Franklin MJ, Berglund D, Sasaki M, Lord CI, Bleazard JB, Duffy JE, Beyenal H, Lewandowski Z. 2003. Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J Immunol 171:4329-4339. http://dx.doi.org/10.4049/jimmunol.171.8.4329.
9. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Hoiby N, Givskov M. 2005. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 151:373-383. http://dx.doi.org/10.1099/mic.0.27463-0.
10. Alhede M, Bjarnsholt T, Jensen PO, Phipps RK, Moser C, Christophersen L, Christensen LD, van Gennip M, Parsek M, Hoiby N, Rasmussen TB, Givskov M. 2009. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology 155:3500-3508. http://dx.doi.org/10.1099/mic.0.031443-0.
11. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. 2005. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56: 879-886. http://dx.doi.org/10.1093/jac/dki338.
12. Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, Lynch SV, Yang K. 2011. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents 37:309-315. http://dx.doi.org/10.1016/j.ijantimicag.2010.12.017.
13. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2:65. http://dx.doi.org/10.3389/fmicb.2011.00065.
14. Sonstein SA, Burnham JC. 1993. Effect of low concentrations of quinolone antibiotics on bacterial virulence mechanisms. Diagn Microbiol Infect Dis 16:277-289. http://dx.doi.org/10.1016/0732-8893(93)90078-L.
15. Wozniak DJ, Keyser R. 2004. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125:62S-69S. http://dx.doi.org/10.1378/chest.125.2-suppl.62S.
16. Fonseca AP, Extremina C, Fonseca AF, Sousa JC. 2004. Effect of subinhibitory concentration of piperacillin/tazobactam on Pseudomonas aeruginosa. J Med Microbiol 53:903-910. http://dx.doi.org/10.1099/jmm.0.45637-0.
17. Alhajlan M, Alhariri M, Omri A. 2013. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 57:2694-2704. http://dx.doi.org/10.1128/AAC.00235-13.
18. Walters MC, III, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 47:317-323. http://dx.doi.org/10.1128/AAC.47.1.317-323.2003.
19. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Caiazza NC, Merritt JH, Brothers KM, O'Toole GA. 2007. Inverse regulation of biofilm formation and swarming motility by Pseudomonas aeruginosa PA14. J Bacteriol 189:3603-3612. http://dx.doi.org/10.1128/JB.01685-06.
21. Peeters E, Nelis HJ, Coenye T. 2008. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods 72:157-165. http://dx.doi.org/10.1016/j.mimet.2007.11.010.
22. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. 1993. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 61:1185-1193.
23. Perez LM, Alvarez BL, Codony F, Fittipaldi M, Adrados B, Penuela G, Morato J. 2010. A new microtitre plate screening method for evaluating the viability of aerobic respiring bacteria in high surface biofilms. Lett Appl Microbiol 51:331-337. http://dx.doi.org/10.1111/j.1472-765X.2010.02902.x.
24. Chatzimoschou A, Katragkou A, Simitsopoulou M, Antachopoulos C, Georgiadou E, Walsh TJ, Roilides E. 2011. Activities of triazoleechinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob Agents Chemother 55:1968-1974. http://dx.doi.org/10.1128/AAC.00959-10.
25. Bodey GP, Valdivieso M, Feld R, Rodriguez V. 1974. Pharmacology of amikacin in humans. Antimicrob Agents Chemother 5:508-512. http://dx.doi.org/10.1128/AAC.5.5.508.
26. Goldfarb J, Wormser GP, Inchiosa MA, Jr, Guideri G, Diaz M, Gandhi R, Goltzman C, Mascia AV. 1986. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol 26:222-226. http://dx.doi.org/10.1002/j.1552-4604.1986.tb02938.x.
27. Fabre D, Bressolle F, Gomeni R, Arich C, Lemesle F, Beziau H, Galtier M. 1991. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 35:3521-2525.
28. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. 2001. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 48:325-327. http://dx.doi.org/10.1093/jac/48.2.325.
29. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J. 2009. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 13:R200. http://dx.doi.org/10.1186/cc8206.
30. Chono S, Tanino T, Seki T, Morimoto K. 2008. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm 34:1090-1096. http://dx.doi.org/10.1080/03639040801958421.
31. Mulcahy H, Charron-Mazenod L, Lewenza S. 2008. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog 4:e1000213. http://dx.doi.org/10.1371/journal.ppat.1000213.
32. Tauber SC, Nau R. 2008. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 1:68-79. http://dx.doi.org/10.2174/1874467210801010068.
33. Labro MT. 2012. Immunomodulatory effects of antimicrobial agents. Part I. Antibacterial and antiviral agents. Expert Rev Anti Infect Ther 10:319-340. http://dx.doi.org/10.1586/eri.12.11.
34. van Gennip M, Christensen LD, Alhede M, Qvortrup K, Jensen PO, Hoiby N, Givskov M, Bjarnsholt T. 2012. Interactions between polymorphonuclear leukocytes and Pseudomonas aeruginosa biofilms on silicone implants in vivo. Infect Immun 80:2601-2607. http://dx.doi.org/10.1128/IAI.06215-11.
35. Jensen ET, Kharazmi A, Lam K, Costerton JW, Hoiby N. 1990. Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun 58:2383-2385.
36. Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, Ciofu O, Mandsberg L, Kharazmi A, Doring G, Givskov M, Hoiby N, Jensen PO. 2010. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 65:57-62. http://dx.doi.org/10.1136/thx.2009.114512.
37. Zhanel GG, Karlowsky JA, Hoban DJ, Davidson RJ. 1991. Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect. Chemotherapy 37:114-121. http://dx.doi.org/10.1159/000238842.
38. Walker SG, Beveridge TJ. 1988. Amikacin disrupts the cell envelope of Pseudomonas aeruginosa ATCC 9027. Can J Microbiol 34:12-18. http://dx.doi.org/10.1139/m88-003.
39. Kadurugamuwa JL, Beveridge TJ. 1997. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 40: 615-621. http://dx.doi.org/10.1093/jac/40.5.615.
40. Gressier B, Brunet C, Dine T, Luyckx M, Ballester L, Cazin M, Cazin JC. 1998. In vitro activity of aminoglycosides on the respiratory burst response in human polymorphonuclear neutrophils. Methods Find Exp Clin Pharmacol 20:819-824. http://dx.doi.org/10.1358/mf.1998.20.10.487532.
41. Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginaka H, Usui T. 1997. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method. Chemotherapy 43:340-345. http://dx.doi.org/10.1159/000239587.
42. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. 2006. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 27:196-200. http://dx.doi.org/10.1016/j.ijantimicag.2005.10.007.
43. Goh EB, Yim G, Tsui W, McClure J, Surette MG, Davies J. 2002. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl Acad Sci U S A 99:17025-17030. http://dx.doi.org/10.1073/pnas.252607699.
44. Garske LA, Beatson SA, Leech AJ, Walsh SL, Bell SC. 2004. Subinhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa. Pathology 36:571-575. http://dx.doi.org/10.1080/00313020400011300.
45. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M. 2008. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:3648-3663. http://dx.doi.org/10.1128/AAC.01230-07.
46. Jensen PO, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L, Moser C, Williams P, Pressler T, Givskov M, Hoiby N. 2007. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 153:1329-1338. http://dx.doi.org/10.1099/mic.0.2006/003863-0.
47. Labro MT, el Benna J. 1990. Comparison of cefodizime with various cephalosporins for their indirect effect on the human neutrophil oxidative burst in vitro. J Antimicrob Chemother 26(Suppl C):49-57. http://dx.doi.org/10.1093/jac/26.suppl-C.49.
48. Schlaeffer F, Blaser J, Laxon J, Zinner S. 1990. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother 25:941-948. http://dx.doi.org/10.1093/jac/25.6.941.
49. Canton E, Peman J, Cabrera E, Velert M, Orero A, Pastor A, Gobernado M. 1999. Killing of Gram-negative bacteria by ciprofloxacin within both healthy human neutrophils and neutrophils with inactivated O2-dependent bactericidal mechanisms. Chemotherapy 45:268-276. http://dx.doi.org/10.1159/000007196.
50. Oldak E, Trafny EA. 2005. Secretion of proteases by Pseudomonas aeruginosa biofilms exposed to ciprofloxacin. Antimicrob Agents Chemother 49:3281-3288. http://dx.doi.org/10.1128/AAC.49.8.3281-3288.2005.
51. Jensen PO, Briales A, Brochmann RP, Wang H, Kragh KN, Kolpen M, Hempel C, Bjarnsholt T, Hoiby N, Ciofu O. 2014. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. Pathog Dis 70:440-443. http://dx.doi.org/10.1111/2049-632X.12120.